Literature DB >> 22804741

Thermal dose fractionation affects tumour physiological response.

Donald E Thrall1, Paolo Maccarini, Paul Stauffer, James Macfall, Marlene Hauck, Stacey Snyder, Beth Case, Keith Linder, Lan Lan, Linda McCall, Mark W Dewhirst.   

Abstract

PURPOSE: It is unknown whether a thermal dose should be administered using a few large fractions with higher temperatures or a larger number of fractions with lower temperatures. To evaluate this we assessed the effect of administering the same total thermal dose, approximately 30 CEM43T(90), in one versus three to four fractions per week, over 5 weeks.
MATERIALS AND METHODS: Canine sarcomas were randomised to receive one of the hyperthermia fractionation schemes along with fractionated radiotherapy. Tumour response was based on changes in tumour volume, oxygenation, water diffusion quantified using MRI, and a panel of histological and immunohistochemical end points.
RESULTS: There was a greater reduction in tumour volume and water diffusion at the end of therapy in tumours receiving one hyperthermia fraction per week. There was a weak but significant association between improved tumour oxygenation 24 h after the first hyperthermia treatment and extent of volume reduction at the end of therapy. Finally, the direction of change of HIF-1α and CA-IX immunoreactivity after the first hyperthermia fraction was similar and there was an inverse relationship between temperature and the direction of change of CA-IX. There were no significant changes in interstitial fluid pressure, VEGF, vWF, apoptosis or necrosis as a function of treatment group or temperature.
CONCLUSIONS: We did not identify an advantage to a three to four per week hyperthermia prescription, and response data pointed to a one per week prescription being superior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22804741      PMCID: PMC3727142          DOI: 10.3109/02656736.2012.689087

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  32 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment.

Authors:  Z Vujaskovic; J M Poulson; A A Gaskin; D E Thrall; R L Page; H C Charles; J R MacFall; D M Brizel; R E Meyer; D M Prescott; T V Samulski; M W Dewhirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

3.  Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.

Authors:  A Italiano; F Delva; S Mathoulin-Pelissier; A Le Cesne; S Bonvalot; P Terrier; M Trassard; J-J Michels; J-Y Blay; J-M Coindre; B Bui
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

4.  Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.

Authors:  J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

5.  Using units of CEM 43 degrees C T90, local hyperthermia thermal dose can be delivered as prescribed.

Authors:  D E Thrall; G L Rosner; C Azuma; S M Larue; B C Case; T Samulski; M W Dewhirst
Journal:  Int J Hyperthermia       Date:  2000 Sep-Oct       Impact factor: 3.914

6.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

7.  Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity.

Authors:  Dorthe M Katschinski; Lu Le; Daniel Heinrich; Klaus F Wagner; Thomas Hofer; Susann G Schindler; Roland H Wenger
Journal:  J Biol Chem       Date:  2002-01-04       Impact factor: 5.157

Review 8.  Cellular responses to combinations of hyperthermia and radiation.

Authors:  W C Dewey; L E Hopwood; S A Sapareto; L E Gerweck
Journal:  Radiology       Date:  1977-05       Impact factor: 11.105

9.  Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients.

Authors:  Corinne M Doll; Michael Milosevic; Melania Pintilie; Richard P Hill; Anthony W Fyles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

10.  NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment.

Authors:  Eui Jung Moon; Pierre Sonveaux; Paolo E Porporato; Pierre Danhier; Bernard Gallez; Ines Batinic-Haberle; Yu-Chih Nien; Thies Schroeder; Mark W Dewhirst
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

View more
  9 in total

1.  Practical considerations for maximizing heat production in a novel thermobrachytherapy seed prototype.

Authors:  Bhoj Gautam; Gregory Warrell; Diana Shvydka; Manny Subramanian; E Ishmael Parsai
Journal:  Med Phys       Date:  2014-02       Impact factor: 4.071

Review 2.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

Review 3.  Temperature matters! And why it should matter to tumor immunologists.

Authors:  Elizabeth A Repasky; Sharon S Evans; Mark W Dewhirst
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

4.  Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors.

Authors:  Alexander F Bagley; Ruth Scherz-Shouval; Peter A Galie; Angela Q Zhang; Jeffrey Wyckoff; Luke Whitesell; Christopher S Chen; Susan Lindquist; Sangeeta N Bhatia
Journal:  Cancer Res       Date:  2015-06-29       Impact factor: 12.701

5.  Hypoxia-Related Marker GLUT-1, CAIX, Proliferative Index and Microvessel Density in Canine Oral Malignant Neoplasia.

Authors:  Valeria Meier; Franco Guscetti; Malgorzata Roos; Stefanie Ohlerth; Martin Pruschy; Carla Rohrer Bley
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

6.  Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model.

Authors:  Michael W Nolan; Tracy L Gieger; Alexander A Karakashian; Mariana N Nikolova-Karakashian; Lysa P Posner; Donald M Roback; Judith N Rivera; Sha Chang
Journal:  Technol Cancer Res Treat       Date:  2017-02-07

Review 7.  Canine Cancer: Strategies in Experimental Therapeutics.

Authors:  Douglas H Thamm
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

Review 8.  Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy.

Authors:  Mark W Dewhirst; James R Oleson; John Kirkpatrick; Timothy W Secomb
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

Review 9.  Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment.

Authors:  Kendall L Langsten; Jong Hyuk Kim; Aaron L Sarver; Mark Dewhirst; Jaime F Modiano
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.